In acute myeloid leukaemia (AML), recurrent genetic abnormalities (RGA) have been identified through systematic genomic studies [1,2,3,4,5] Based on these RGAs, the World Health Organization (WHO 2022 ...
First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia Our study demonstrated that ...
AML is a genetically heterogeneous disease, particularly in older patients. In patients older than 60 years, survival rates are variable after the most important curative approach, intensive ...
Acute myeloid leukemia can often appear suddenly in patients, without any detectable early symptoms. However, new research has identified the origins of AML, which can be detectable more than 5 years ...
Although induction chemotherapy results in remission in many older patients with acute myeloid leukemia (AML), relapse is common and overall survival is poor. We conducted a phase 3, randomized, ...
One of the rarer complications of acute myeloid leukemia (AML) is the involvement of the central nervous system (CNS). This complication can occur in both children and adults. Children will undergo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results